Patents by Inventor Vincent Mikol

Vincent Mikol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
    Publication number: 20160200811
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: November 20, 2015
    Publication date: July 14, 2016
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
    Patent number: 9382312
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 5, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Humanized anti-CXCR5 antibodies, derivatives thereof and their use
    Patent number: 9243067
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 26, 2016
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Humanized anti-CXCR5 antibodies, derivatives thereof and their use
    Patent number: 9228019
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 5, 2016
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Dual variable region antibody-like binding proteins having cross-over binding region orientation
    Patent number: 9221917
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 29, 2015
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Chirstian Biel, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Dual variable region antibody-like binding proteins having cross-over binding region orientation
    Patent number: 9181349
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 10, 2015
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Chirstian Biel, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Humanized anti-CXCR5 antibodies, derivatives thereof and their use
    Patent number: 9175087
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: November 3, 2015
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF
    Publication number: 20150098939
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 9, 2015
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
  • Humanized anti-CXCR5 antibodies, derivatives thereof and their use
    Patent number: 8980262
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 17, 2015
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • ANTIBODIES THAT SPECIFICALLY BIND TO THE EPHA2 RECEPTOR
    Publication number: 20150044197
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Application
    Filed: January 15, 2014
    Publication date: February 12, 2015
    Applicant: Sanofi
    Inventors: Herve BOUCHARD, Alain COMMERCON, Claudia FROMOND, Vincent MIKOL, Fabienne PARKER, Ingrid SASSOON, Daniel TAVARES
  • IN SILICO AFFINITY MATURATION
    Publication number: 20140335102
    Abstract: Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 13, 2014
    Applicant: Sanofi
    Inventors: Michael Oberlin, Romano Kroemer, Vincent Mikol, Hervé Minoux, Nicolas Baurin
  • Antagonist antibodies and their fab fragments against GPVI and uses thereof
    Patent number: 8852593
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 7, 2014
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE
    Publication number: 20140105890
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Marc DUCHESNE, Vincent MIKOL, Souad NAIMI, Laurent PRADIER, Yi SHI
  • Antibodies that specifically bind to the EphA2 receptor
    Patent number: 8668910
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 11, 2014
    Assignee: Sanofi
    Inventors: Herve Bouchard, Alain Commercon, Claudia Fromond, Vincent Mikol, Fabienne Parker, Ingrid Sassoon, Daniel Tavares
  • Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
    Publication number: 20140056895
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 27, 2014
    Applicant: SANOFI
    Inventors: Nicolas Baurin, Chirstian Biel, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Humanized anti-CXCR5 antibodies, derivatives thereof and their use
    Patent number: 8647622
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: February 11, 2014
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicolas Baurin
  • ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES
    Publication number: 20140023649
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 23, 2014
    Applicant: SANOFI
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
    Publication number: 20140011238
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 9, 2014
    Applicant: SANOFI
    Inventors: Nicolas Baurin, Chirstian Biel, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
    Publication number: 20130345404
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: March 14, 2013
    Publication date: December 26, 2013
    Applicant: SANOFI
    Inventors: Nicolas Baurin, Chirstian Biel, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
    Patent number: 8614299
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 24, 2013
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi